Changes in Hong Kong stocks | Zaiding Pharmaceutical (09688) rose more than 4% to announce that bemastuzumab used for FGFR2b positive first-line gastric cancer phase III study data obtained positive results

Zhitongcaijing · 5d ago

The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) rose by more than 4%. As of press release, it had risen 4.31% to HK$29.05, with a turnover of HK$87.0209 million.

According to the news, according to Zaiding Pharmaceutical's official WeChat account, on June 30, Zaiding Pharmaceutical announced that the phase III FORTITUDE-101 clinical study evaluating bemastuzumab combined chemotherapy (mFOLFOX6) as first-line treatment reached its main endpoint overall survival (OS) in a predetermined mid-term analysis. In patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction (G/GEJ) cancer with overexpression of FGFR2b and non-HER2 positive, pemastuzumab combination chemotherapy compared with placebo combination chemotherapy showed significant statistically significant and clinically significant improvements in overall survival (OS).

According to reports, Zaiding Pharmaceutical has the right to develop and commercialize bemastuzumab in mainland China, Hong Kong, Macau, and Taiwan. Bemastuzumab has been recognized as a breakthrough therapy by the Drug Evaluation Center (CDE) of the China National Drug Administration for the treatment of FGFR2b positive gastric cancer and gastroesophageal junction cancer.

In addition, a phase III study on first-line treatment of gastric cancer patients with bemastuzumab combined with chemotherapy and navulizumab is also ongoing. The data is expected to be released in the second half of 2025.